NYSE:CATX Perspective Therapeutics (CATX) Stock Price, News & Analysis $13.22 -1.88 (-12.45%) (As of 02:52 PM ET) Add Compare Share Share Today's Range$12.95▼$15.2150-Day Range$10.61▼$15.8452-Week Range$2.20▼$19.05Volume1.56 million shsAverage Volume626,867 shsMarket Capitalization$891.42 millionP/E RatioN/ADividend YieldN/APrice Target$19.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Perspective Therapeutics alerts: Email Address Perspective Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside49.8% Upside$19.80 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.25Based on 3 Articles This WeekInsider TradingAcquiring Shares$17,658 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.86) to ($0.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.74 out of 5 starsMedical Sector666th out of 927 stocksSurgical & Medical Instruments Industry79th out of 101 stocks 3.5 Analyst's Opinion Consensus RatingPerspective Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePerspective Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Perspective Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CATX. Previous Next 0.0 Dividend Strength Dividend YieldPerspective Therapeutics does not currently pay a dividend.Dividend GrowthPerspective Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CATX. Previous Next 2.4 News and Social Media Coverage News SentimentPerspective Therapeutics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Perspective Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for CATX on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows5 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Perspective Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $17,658.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.52% of the stock of Perspective Therapeutics is held by insiders.Percentage Held by Institutions54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Perspective Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Perspective Therapeutics are expected to decrease in the coming year, from ($0.86) to ($0.99) per share.Price to Book Value per Share RatioPerspective Therapeutics has a P/B Ratio of 4.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Capital TrendsMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukraine was used to cyberattacks. But the WhisperGate attack just before Russia's full-scale invasion was different. It was larger... and it was aimed at dismantling Ukraine's critical infrastructure. The company's unique expertise and scalable approach allowed them to nearly double revenues between 2021-2023, and they've added another $20 million in new sales orders this year alone. There is no denying - the opportunity here is massive.Click here to learn how a small company is joining the ranks of Lockheed Martin and Raytheon About Perspective TherapeuticsPerspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Read More CATX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CATX Stock News HeadlinesSeptember 11, 2024 | americanbankingnews.comCantor Fitzgerald Reaffirms "Overweight" Rating for Perspective Therapeutics (NYSE:CATX)September 10, 2024 | markets.businessinsider.comPerspective Therapeutics Presents at the World Molecular Imaging Congress 2024September 16, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…September 6, 2024 | seekingalpha.comPerspective gets FDA fast track status for radiopharmaceutical VMT01September 5, 2024 | markets.businessinsider.comPerspective Therapeutics: FDA Grants Fast Track Designation For Development Of 212Pb VMT01September 5, 2024 | globenewswire.comPerspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive MelanomaAugust 28, 2024 | globenewswire.comPerspective Therapeutics to Participate in Upcoming Investor Conferences in SeptemberAugust 26, 2024 | seekingalpha.comTScan Therapeutics: Speculative Buy With Near-Term Catalysts In OncologySeptember 16, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…August 16, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)August 14, 2024 | finance.yahoo.comCATX Jan 2025 12.500 call (CATX250117C00012500)August 14, 2024 | markets.businessinsider.comBuy Rating Justified by Perspective Therapeutics’s Promising Clinical Data and Strategic ExpansionAugust 14, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Perspective Therapeutics (CATX)August 13, 2024 | markets.businessinsider.comBuy Rating on Perspective Therapeutics: Advancing Clinical Programs and Strong Financials Promise Value CreationAugust 12, 2024 | investorplace.comCATX Stock Earnings: Perspective Therapeutics Beats EPS, Beats Revenue for Q2 2024August 12, 2024 | globenewswire.comPerspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 ResultsAugust 12, 2024 | markets.businessinsider.comHere's what to expect from Perspective Therapeutics's earningsAugust 5, 2024 | seekingalpha.comThe Prognosis For Perspective TherapeuticsSee More Headlines Receive CATX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:CATX CUSIPN/A CIK728387 Webwww.perspectivetherapeutics.com Phone206-676-0900Fax509-267-3670Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$19.80 High Stock Price Target$27.00 Low Stock Price Target$14.00 Potential Upside/Downside+50.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,510,000.00 Net MarginsN/A Pretax Margin-3,641.05% Return on Equity-32.87% Return on Assets-28.06% Debt Debt-to-Equity RatioN/A Current Ratio27.73 Quick Ratio27.73 Sales & Book Value Annual Sales$1.43 million Price / Sales622.43 Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book4.94Miscellaneous Outstanding Shares67,430,000Free Float60,071,000Market Cap$890.08 million OptionableOptionable Beta1.44 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Johan M. Spoor (Age 52)CEO & Director Comp: $855.78kMr. Jonathan R. Hunt (Age 57)CFO & Co-Principal Financial Officer Comp: $944.35kDr. Markus Puhlmann M.B.A. (Age 58)M.D., Chief Medical Officer Comp: $633.14kMr. Shane CobbExecutive Vice President of OperationsMr. Mark J. Austin CPA (Age 37)VP of Finance, Corporate Controller, Co-Principal Financial, Principal Acc. Officer & Secretary Dr. Michael K. Schultz Ph.D.Chief Science OfficerMr. Andrew BrightExecutive Vice President of BrachytherapyMr. Amos Hedt BAPGradDip, Chief Business Strategy OfficerDr. Frances L. Johnson M.D.Chief Innovation OfficerMr. David Hauser Ph.D.Senior Vice President of Clinical OperationsMore ExecutivesKey CompetitorsAxonicsNASDAQ:AXNXEnvistaNYSE:NVSTTandem Diabetes CareNASDAQ:TNDMInari MedicalNASDAQ:NARILivaNovaNASDAQ:LIVNView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Sold 13,250,683 shares on 8/19/2024Ownership: 0.325%Deerfield Management Company L.P. Series CSold 25,359,873 shares on 8/15/2024Ownership: 4.526%Affinity Asset Advisors LLCSold 4,550,000 shares on 8/15/2024Ownership: 0.883%The Manufacturers Life Insurance Company Bought 18,842 shares on 8/15/2024Ownership: 0.030%Point72 DIFC LtdBought 11,842 shares on 8/14/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions CATX Stock Analysis - Frequently Asked Questions How have CATX shares performed this year? Perspective Therapeutics' stock was trading at $11.90 on January 1st, 2024. Since then, CATX shares have increased by 11.1% and is now trading at $13.22. View the best growth stocks for 2024 here. How were Perspective Therapeutics' earnings last quarter? Perspective Therapeutics, Inc. (NYSE:CATX) released its quarterly earnings data on Monday, August, 12th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.04. The business had revenue of $0.53 million for the quarter. When did Perspective Therapeutics' stock split? Perspective Therapeutics's stock reverse split on the morning of Monday, June 17th 2024. The 1-10 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Perspective Therapeutics' major shareholders? Perspective Therapeutics' top institutional investors include Deerfield Management Company L.P. Series C (4.53%), Marshall Wace LLP (2.06%), Affinity Asset Advisors LLC (0.88%) and Ally Bridge Group NY LLC (0.64%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Lori A Woods, Markus Puhlmann, Robert F Williamson III, Jonathan Robert Hunt and Johan M Spoor. View institutional ownership trends. How do I buy shares of Perspective Therapeutics? Shares of CATX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CATX) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CATX with Qtrade Free CATX Stock Alerts